|
|||||
|
|
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial |
|
| Authors: | Vibeke Strand Joel M. Kremer David Gruben Sriram Krishnaswami Samuel H. Zwillich Gene V. Wallenstein |
| Affiliation: | 1. Stanford University School of Medicine, Palo Alto, California;2. Albany Medical College, Albany, New York;3. Pfizer Inc, Groton, Connecticut |
| Abstract: | |
| Keywords: | |